According to the Centers for Disease Control and Prevention (CDC), as of 2017, 65.3% of women between the ages of 15 and 49 in the United States use a form of birth control. Of this population, 10.4% ...
The Depo-Provera birth control shot has been linked to an increased risk of a type of brain tumors known as meningiomas. Women who received the Depo shot and were diagnosed with meningioma brain ...
For decades, Depo-Provera has been presented as a game-changing contraceptive—a quick injection every three months that promised simplicity and effectiveness. For millions of women worldwide, it ...
WESTWEGO, Louisiana — Robin Phillip’s fresh haircut is dyed her favorite color — green. But beneath the dye job is a scar that runs along the side of her head, the result of two craniotomies. For ...
Jul. 24, 2025 7:00 AM ETPfizer Inc. (PFE), PFE:CA Mahyar Etminan, one of the authors of ‘the Frey study’, said: “Given the elevated risk of meningioma with medroxyprogesterone, women may opt to ...
The FDA has approved a label change on the long-acting injectable contraceptive depot medroxyprogesterone acetate, commonly known as Depo-Provera, to warn users of a potential risk of meningioma. The ...
"It could be big. I think it could be as big as some of the others we've gotten here," Anapol Weiss shareholder Kila Baldwin said. In March, neurosurgeons and researchers in France published a large ...
Since the beginning of the year, there has been a rise in the number of lawsuits against pharma giant Pfizer over its injectable contraception, Depo-Provera. Consumers have increasingly joined ...
At a Case Management Conference in the Multi District Litigation against Pfizer Inc. (NYSE:PFE), the Honorable M. Casey Rodgers set a date for the first Trial, which will take place in December 2026, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results